Literature DB >> 35352058

Zooming in on dendritic cells for CD40 agonists.

Julian Hübner1, Falk Nimmerjahn2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35352058     DOI： 10.1038/s43018-022-00340-x

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


× No keyword cloud information.
  13 in total

1.  Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Science       Date:  2011-08-19       Impact factor: 47.728

Review 2.  CD40 Agonist Antibodies in Cancer Immunotherapy.

Authors:  Robert H Vonderheide
Journal:  Annu Rev Med       Date:  2019-08-14       Impact factor: 13.739

Review 3.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

Review 4.  The Use of Anti-CD40 mAb in Cancer.

Authors:  Marcus Remer; Ann White; Martin Glennie; Aymen Al-Shamkhani; Peter Johnson
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

5.  Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.

Authors:  Rony Dahan; Bryan C Barnhart; Fubin Li; Aaron P Yamniuk; Alan J Korman; Jeffrey V Ravetch
Journal:  Cancer Cell       Date:  2016-06-02       Impact factor: 31.743

6.  Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.

Authors:  David A Knorr; Rony Dahan; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-08       Impact factor: 11.205

7.  Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

Authors:  Ann L White; H T Claude Chan; Ali Roghanian; Ruth R French; C Ian Mockridge; Alison L Tutt; Sandra V Dixon; Daniel Ajona; J Sjef Verbeek; Aymen Al-Shamkhani; Mark S Cragg; Stephen A Beers; Martin J Glennie
Journal:  J Immunol       Date:  2011-07-08       Impact factor: 5.422

8.  Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.

Authors:  Ann L White; Lang Dou; H T Claude Chan; Vikki L Field; C Ian Mockridge; Kane Moss; Emily L Williams; Steven G Booth; Ruth R French; Elizabeth A Potter; Cherié Butts; Aymen Al-Shamkhani; Mark S Cragg; J Sjef Verbeek; Peter W M Johnson; Martin J Glennie; Stephen A Beers
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

9.  Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

Authors:  Xiaojie Yu; H T Claude Chan; Christian M Orr; Osman Dadas; Steven G Booth; Lekh N Dahal; Christine A Penfold; Lyn O'Brien; C Ian Mockridge; Ruth R French; Patrick Duriez; Leon R Douglas; Arwen R Pearson; Mark S Cragg; Ivo Tews; Martin J Glennie; Ann L White
Journal:  Cancer Cell       Date:  2018-03-22       Impact factor: 31.743

10.  Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.

Authors:  Xiaojie Yu; H T Claude Chan; Hayden Fisher; Christine A Penfold; Jinny Kim; Tatyana Inzhelevskaya; C Ian Mockridge; Ruth R French; Patrick J Duriez; Leon R Douglas; Vikki English; J Sjef Verbeek; Ann L White; Ivo Tews; Martin J Glennie; Mark S Cragg
Journal:  Cancer Cell       Date:  2020-05-21       Impact factor: 31.743
View more
  1 in total

1.  Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy.

Authors:  Ran Salomon; Rony Dahan
Journal:  Front Immunol       Date:  2022-07-13       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.